Sinovac's Acceptance In Bahrain: What's The Verdict?

The Sinovac vaccine has been a topic of discussion for many countries during the COVID-19 pandemic, and Bahrain is no exception. As the pandemic unfolded, Bahrain had to make critical decisions regarding vaccine approval and implementation to protect its citizens and residents. The approval of the Sinovac vaccine in Bahrain is a significant development, and it's essential to understand the context and implications of this decision. This paragraph aims to introduce the topic and provide a glimpse into the considerations and outcomes surrounding the acceptance of the Sinovac vaccine in Bahrain.

Sinovac is accepted in Bahrain for entry

In addition to Sinovac, Bahrain has also approved other vaccines for use, including Pfizer-BioNTech, Sinopharm, Oxford-Astra Zenica, and Sputnik V. The country has offered its citizens a choice of which vaccine to take, with Pfizer being the leading vaccine type in Bahrain.

It is important to note that entry requirements may change, and it is always recommended to check for the latest updates before travelling. As of February 2022, a Kuwait Travel Registration is no longer required for Bahraini citizens entering Kuwait. However, a 7-day quarantine period is mandatory upon arrival, and a valid passport with 6 months validity is required for entry.

For those who have been vaccinated with Sinovac and are planning to travel to Bahrain, it is advisable to stay up to date with the latest travel advice and guidelines provided by the Bahraini government and health authorities. This will ensure a smooth entry and help protect the health and safety of all travellers and residents in Bahrain.

Sinovac is not enough for full vaccination

Sinovac is a Chinese-made COVID-19 vaccine that has been approved for use in several countries, including Bahrain. However, it is important to note that having the Sinovac vaccine alone is not enough to be considered fully vaccinated in Bahrain.

In Bahrain, the definition of full vaccination has changed over time and varies depending on the vaccine type. As of December 2021, the Bahraini government stated that full vaccination involves having two doses of the Sinovac vaccine, along with a booster shot of a different vaccine, such as AstraZeneca, Janssen, Moderna, or Pfizer. This is specifically for individuals who are travelling to the country for Hajj and Umrah pilgrimages.

The requirement for a booster shot with a different vaccine is due to the evolving nature of the SARS-CoV-2 virus and its variants. The Sinovac vaccine, while effective, may not provide sufficient protection against certain variants that have emerged since the vaccine's development. By requiring a booster shot from a different vaccine type, Bahrain aims to ensure that individuals have maximum protection against the virus and its variants.

Additionally, there have been studies suggesting that the Sinovac vaccine provides only partial protection against SARS-CoV-2 infection. In a case study of a Bahraini family, it was observed that a majority of the family members who were infected had received the Sinovac vaccine. While the vaccine reduced casualties, it could not prevent infection entirely. This further emphasizes the importance of having a diverse vaccination strategy that includes booster shots from different vaccine types to maximize protection.

Therefore, while Sinovac is accepted in Bahrain and provides a level of protection against COVID-19, it is not sufficient on its own to be considered fully vaccinated. Individuals who have only received Sinovac may still be required to follow additional health protocols, such as providing a negative PCR test result and undergoing institutional quarantine upon arrival in Bahrain.

The efficacy of Sinovac

The Sinovac COVID-19 vaccine, also known as CoronaVac, has been deemed effective by the World Health Organization (WHO). According to the WHO's Strategic Advisory Group of Experts (SAGE), the vaccine has shown efficacy levels compatible with the organisation's requirements. The chair of the WHO advisory panel, Alejandro Cravioto, stated that the vaccine data shared by Sinovac indicates an efficacy level of about 50%, and preferably close to or above 70%. This meets the WHO's criteria for emergency use listing.

However, it is important to note that the efficacy rates of the Sinovac vaccine have varied across different trials conducted in Brazil, Turkey, and Indonesia. The varied efficacy readings range from 50.4% to 83.5%. For instance, researchers in Turkey reported an efficacy rate of 91.25%, while those in Indonesia reported a rate of 65%. The Brazilian trials, which were the largest with around 13,000 participants, found the vaccine to be 50.4% effective in preventing symptomatic infections.

These differences in efficacy rates can be attributed to various factors, including trial size, patient criteria, duration of post-vaccination observation, target groups, and the prevalence of the virus in each site. For example, the higher rate in Turkey may be due to the smaller sample size of 1,322 people out of 7,000 volunteers. In contrast, the lower rate in Brazil could be a result of more rampant infections and the inclusion of mild infections in the trials.

Despite the varying efficacy rates, Sinovac maintains that its vaccine is safe and effective. The company acknowledges that its trial designs differ among countries, but the results are sufficient to prove the vaccine's safety and efficacy. The head of the vaccine research group International Vaccine Institute, Jerome Kim, agrees that it is possible to combine data from multiple studies with varied trial designs, but it may involve additional statistical manipulation, potentially impacting the interpretation of the results.

While the efficacy rates of the Sinovac vaccine may vary, it is still recognised as a valid vaccination option. This is particularly important for developing countries with limited access to vaccines produced by Western drugmakers.

The safety of Sinovac

The Sinovac COVID-19 vaccine, also known as the CoronaVac, is a vaccine created by Beijing-based pharmaceutical company Sinovac. It is the second China-made vaccine to be approved by the World Health Organisation (WHO) for use against COVID-19. The WHO has thoroughly assessed the quality, safety, and efficacy data of the Sinovac vaccine and has recommended its use for people aged 18 and above. However, due to the small number of participants in clinical trials, data on the safety of the vaccine is limited for those above 60. Nevertheless, the available data suggests that the vaccine is likely safe and protective for older persons.

The Sinovac vaccine is an inactivated form of the COVID-19 virus, where the viral particles are killed so they cannot replicate, but the surface spike protein is kept intact to trigger the body's immune system to create antibodies. Inactivated viruses are a tried and tested form of vaccine technology and have been traditionally used to create vaccines over the past century. For example, the flu, polio, and hepatitis A vaccines all use this method.

The most common side effects reported by those who received the Sinovac vaccine were injection site pain and soreness, fatigue, diarrhoea, and muscle weakness. Most of these side effects were mild and lasted for only two days. Clinical trial data for the vaccine has shown that trial participants who received the Sinovac vaccine reported a lower occurrence of fever in comparison to mRNA vaccines like the Pfizer-BioNtech and Moderna vaccines.

The vaccine is safe for pregnant and breastfeeding women, as it is biologically and clinically unlikely to pose a risk to children being breastfed. The vaccine shares a safety profile similar to many other well-documented vaccines, such as the Hepatitis B vaccine, and so it is expected to be similarly effective for pregnant women.

The WHO includes those with Human Immunodeficiency Virus (HIV) or who are immunocompromised as part of the recommended group for vaccination with the Sinovac vaccine. This is because these groups of patients have a higher risk of experiencing severe COVID-19, and although they have not been included in clinical trials, the Sinovac vaccine is a non-replicating vaccine and is therefore generally safe.

The use of Sinovac in Bahrain

Sinovac is a Chinese COVID-19 vaccine that has been approved for use in Bahrain. The Bahraini government approved the vaccine following its earlier approval of the Pfizer-BioNTech vaccine. The Sinovac vaccine was also approved for use in Saudi Arabia for Hajj and Umrah pilgrimages.

In Bahrain, the Sinovac vaccine was made available to the public through a free vaccination program. The kingdom participated in the third phase of the Sinovac clinical trials, and the vaccine was widely chosen due to the strong belief in the traditional method of using inactivated viruses for vaccination.

The efficacy of the Sinovac vaccine was studied in Bahrain, with results showing that it provided partial protection against SARS-CoV-2 infection. However, the vaccine was found to be less effective in preventing infection compared to other vaccines. As a result, Bahrain started offering Pfizer boosters to Sinovac vaccine recipients.

Frequently asked questions